Answers are grounded in this paper and cite their sources.
Explores drug delivery methods using axitinib in cancer therapy, highlighting therapeutic advancements and opportunities.
Despite progress in targeted cancer treatment, sustained-release platforms enhance therapeutic potential while minimizing off-target effects. Studies are increasingly being conducted on axitinib combined with compatible anticancer agents after pharmacokinetic and safety considerations. These combinations may alter angiogenic signaling and delay the onset of resistance. As clinical priorities focus on minimizing toxicity, formulation innovations will be crucial to maximize the therapeutic potential of axitinib.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: